Felicia C Goldstein1, Kyle Steenland2, Liping Zhao3, Whitney Wharton1, Allan I Levey1, Ihab Hajjar1,4. 1. Department of Neurology, School of Medicine, Emory University, Atlanta, Georgia. 2. Department of Environmental and Occupational Health, School of Public Health, Emory University, Atlanta, Georgia. 3. Department of Biostatistics and Bioinformatics, School of Public Health, Emory University, Atlanta, Georgia. 4. Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Abstract
OBJECTIVES: To examine the risk associated with the use of proton pump inhibitors (PPIs) of conversion to mild cognitive impairment (MCI), dementia, and specifically Alzheimer's disease (AD). DESIGN: Observational, longitudinal study. SETTING: Tertiary academic Alzheimer's Disease Centers funded by the National Institute on Aging. PARTICIPANTS: Research volunteers aged 50 and older with two to six annual visits; 884 were taking PPIs at every visit, 1,925 took PPIs intermittently, and 7,677 never reported taking PPIs. All had baseline normal cognition or MCI. MEASUREMENTS: Multivariable Cox regression analyses evaluated the association between PPI use and annual conversion of baseline normal cognition to MCI or dementia or annual conversion of baseline MCI to dementia, controlling for demographic characteristics, vascular comorbidities, mood, and use of anticholinergics and histamine-2 receptor antagonists. RESULTS: Continuous (always vs never) PPI use was associated with lower risk of decline in cognitive function (hazard ratio (HR) = 0.78, 95% confidence interval (CI) =0.66-0.93, P = .005) and lower risk of conversion to MCI or AD (HR = 0.82, 95% CI = 0.69-0.98, P = .03). Intermittent use was also associated with lower risk of decline in cognitive function (HR = 0.84, 95% CI = 0.76-0.93, P = .001) and risk of conversion to MCI or AD (HR = 0.82, 95% CI = 0.74-0.91, P = .001). This lower risk was found for persons with normal cognition or MCI. CONCLUSION: Proton pump inhibitors were not associated with greater risk of dementia or of AD, in contrast to recent reports. Study limitations include reliance on self-reported PPI use and lack of dispensing data. Prospective studies are needed to confirm these results to guide empirically based clinical treatment recommendations.
OBJECTIVES: To examine the risk associated with the use of proton pump inhibitors (PPIs) of conversion to mild cognitive impairment (MCI), dementia, and specifically Alzheimer's disease (AD). DESIGN: Observational, longitudinal study. SETTING: Tertiary academic Alzheimer's Disease Centers funded by the National Institute on Aging. PARTICIPANTS: Research volunteers aged 50 and older with two to six annual visits; 884 were taking PPIs at every visit, 1,925 took PPIs intermittently, and 7,677 never reported taking PPIs. All had baseline normal cognition or MCI. MEASUREMENTS: Multivariable Cox regression analyses evaluated the association between PPI use and annual conversion of baseline normal cognition to MCI or dementia or annual conversion of baseline MCI to dementia, controlling for demographic characteristics, vascular comorbidities, mood, and use of anticholinergics and histamine-2 receptor antagonists. RESULTS: Continuous (always vs never) PPI use was associated with lower risk of decline in cognitive function (hazard ratio (HR) = 0.78, 95% confidence interval (CI) =0.66-0.93, P = .005) and lower risk of conversion to MCI or AD (HR = 0.82, 95% CI = 0.69-0.98, P = .03). Intermittent use was also associated with lower risk of decline in cognitive function (HR = 0.84, 95% CI = 0.76-0.93, P = .001) and risk of conversion to MCI or AD (HR = 0.82, 95% CI = 0.74-0.91, P = .001). This lower risk was found for persons with normal cognition or MCI. CONCLUSION:Proton pump inhibitors were not associated with greater risk of dementia or of AD, in contrast to recent reports. Study limitations include reliance on self-reported PPI use and lack of dispensing data. Prospective studies are needed to confirm these results to guide empirically based clinical treatment recommendations.
Authors: John Riley McCarten; Pauline Anderson; Michael A Kuskowski; Susan E McPherson; Soo Borson; Maurice W Dysken Journal: J Am Geriatr Soc Date: 2012-02 Impact factor: 5.562
Authors: Andrea Bradford; Mark E Kunik; Paul Schulz; Susan P Williams; Hardeep Singh Journal: Alzheimer Dis Assoc Disord Date: 2009 Oct-Dec Impact factor: 2.703
Authors: Shelly L Gray; Rod Walker; Sascha Dublin; Sebastien Haneuse; Paul K Crane; John C S Breitner; James Bowen; Wayne McCormick; Eric B Larson Journal: J Am Geriatr Soc Date: 2011-02 Impact factor: 5.562
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Taylor J Krivanek; Seth A Gale; Brittany M McFeeley; Casey M Nicastri; Kirk R Daffner Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Hyo Geun Choi; Joo-Hee Kim; Ji Hee Kim; Eun Soo Kim; Ha Young Park; Kyueng-Whan Min; Mi Jung Kwon Journal: Alzheimers Res Ther Date: 2022-07-01 Impact factor: 8.823